<?xml version="1.0" encoding="UTF-8"?>
<p>Boceprevir and telaprevir were administered through regular clinical care without masking (open label). All treatment doses were provided according to the standard Food and Drug Administration labeling for the two drugs. Patient compliance was monitored at regular intervals by a team comprised of a pharmacist (AH) and a nurse practitioner (AC). This trial consisted of two parallel groups: group 1—boceprevir [200 mg capsules, 800 mg TID p.o] and Peg-IFN/RBV and group 2—telaprevir (375mg capsules, 750 mg TID p.o.) and Peg-IFN/RBV.</p>
